Intermittent HIV triple therapy study in real life
Part of Immune system & allergy, Infections clinical trials.
This study looks at how well intermittent triple therapy works for people with HIV in real-world settings. It may help researchers understand if taking breaks from standard treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are living with HIV
- You receive care at the Trait d'Union/Infectious Diseases department in Strasbourg
- You had intermittent triple therapy between January 1, 2017 and January 31, 2024
- You (or your legal representative) have not objected to your data being used for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that follows people to better understand how HIV and other infections (like sexually transmitted infections) happen and change over time. It may help researchers improve prevention and care, but it is mainly for monitoring rather than testing a new treatment.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
This is an observational study that follows people with HIV who are taking HIV medicines (antiretroviral therapy). It may help researchers understand how treatment is going and what factors relate to doing well on therapy.
This trial compares two different HIV treatment plans: keeping you on a 2-drug regimen versus switching to a 3-drug regimen. It’s designed for people whose HIV is well controlled and looks at whether the switch is safe and effective.
This study follows adults with HIV over time to compare different groups based on how stable their virus levels are. It may help researchers understand who can safely interrupt treatment and who should stay on it, and how immune health changes.
This study looks at a planned, supervised “treatment interruption” period for people with HIV who are very well controlled on HIV medicines. It mainly aims to understand what happens when therapy is paused and how to reduce the risk of passing HIV to others.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.